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ABSTRACT 
BLM has key roles in homologous recombination repair, telomere maintenance and DNA 
replication. Germ-line mutations in the BLM gene causes Bloom’s syndrome, a rare disorder 
characterised by premature aging and predisposition to multiple cancers including breast 
cancer. The clinicopathological significance of BLM in sporadic breast cancers is unknown. 
We investigated BLM mRNA expression in the Molecular Taxonomy of Breast Cancer 
International Consortium cohort (n=1950) and validated in an external dataset of 2413 
tumours.  BLM protein level was evaluated in the Nottingham Tenovus series comprising 
1650 breast tumours. BLM mRNA overexpression was significantly associated with  high 
histological grade, larger tumour size, ER negative, PgR negative and triple negative 
phenotypes (ps<0.0001). BLM mRNA overexpression was also linked to aggressive 
molecular phenotypes including PAM50.Her2 (p<0.0001), PAM50.Basal (p<0.0001) and 
PAM50.LumB (p<0.0001) and Genufu subtype (ER+/Her2-/High proliferation) (p<0.0001). 
PAM50.LumA tumours and Genufu subtype (ER+/Her2-/low proliferation) were more likely 
to express low levels of BLM mRNA (ps<0.0001). Integrative molecular clusters (intClust) 
intClust.1 (p<0.0001), intClust.5 (p<0.0001), intClust.9 (p<0.0001) and intClust.10 
(p<0.0001) were also more likely in tumours with high BLM mRNA expression. BLM mRNA 
overexpression was associated with poor breast cancer specific survival (BCSS) 
(ps<0.000001). At the protein level, altered sub-cellular localisation with high cytoplasmic 
BLM and low nuclear BLM was linked to aggressive phenotypes. In multivariate analysis, 
BLM mRNA and BLM protein levels independently influenced BCSS (p=0.03). This is the 
first and the largest study to provide evidence that BLM is a promising biomarker in breast 
cancer.  
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INTRODUCTION 
 
Blooms syndrome helicase (BLM) is a key member of the RecQ family of DNA helicases 
and essential for the maintenance of genomic stability. BLM is an ATP-dependent 3’-5’ DNA 
helicase involved in unwinding a variety of DNA substrates that can arise during DNA 
replication and repair (1-5).  BLM has important roles in the initiation and regulation of 
homologous recombination (HR) repair of DSB (double-strand breaks). In addition, BLM is 
required for Holliday junction dissolution during the terminal stages of HR. To accomplish its 
various biological functions, BLM interacts with several DNA repair factors including 
topoisomerase III, hRMI1, hRMI2 and Rad51. BLM is also part of the BRCA1-associated 
genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, 
ATM, PMS2 and the RAD50-MRE11-NBS1 protein complex (6). In addition to its DNA 
repair function, BLM is involved in the processing of stalled replication forks during 
replication and in telomere maintenance in cells (1-5).   
 
Bloom’s syndrome (BS) is a rare disorder caused by germ-line mutation in the BLM gene. BS 
is characterised by cancer predisposition, growth retardation, immunodeficiency, sunlight 
hypersensitivity and impaired fertility (7). BLM germ-line mutation results in dramatic 
reduction in BLM mRNA levels and BLM protein expression leading to extensive 
chromosomal instability manifested classically as excessive frequency of sister chromatid 
exchanges (SCEs) in BS cells (1-5).  BS patients are prone to develop leukemia, lymphomas 
and a variety of epithelial cancers including breast cancers (7). Interestingly, polymorphisms 
in the BLM gene have been associated with increased risk of development of sporadic breast 
cancers (8).  In preclinical models, depletion of BLM by shRNA not only reduced 
proliferation in cells (9) but also sensitized them to chemotherapeutic agents such as 
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camptothecins, cisplatin, 5-fluoruracil and hydroxyurea treatment (1-5, 7). BLM is an 
attractive anti-cancer drug target and small molecule inhibitors of BLM are currently under 
pre-clinical development (10). However, target validation studies including prognostic and/or 
predictive significance of BLM in human sporadic tumours have not been reported and 
therefore remain largely unknown. We hypothesised that BLM may be dysregulated in 
sporadic breast cancers and influence clinical outcomes in patients. In this study, we present 
the first and the largest comprehensive study providing compelling evidence that altered 
BLM expression has prognostic and predictive significance in patients. Our data suggest that 
BLM is a rational target in breast cancer. 
 
MATERIALS AND METHODS 
BLM gene expression: METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort was evaluated for BLM gene expression. The METABRIC study 
protocol, detailing the molecular profiling methodology in a cohort of 1980 breast cancer 
samples is described by Curtis et al (11).  Patient demographics are summarized in 
supplementary Table S1 of supporting information. Estrogen receptor (ER) positive and/or 
lymphnode negative patients did not receive adjuvant chemotherapy.  ER negative and/or 
lymphnode positive patients received adjuvant chemotherapy.  RNA was extracted from fresh 
frozen tumours and subjected to transcriptional profiling on the Illumina HT-12 v3 platform.  
The data was pre-processed and normalized as described previously (11). BLM expression 
was investigated in this data set. There was only one probe for BLM (BLM probe id: 
ILM_1709484) in the Illumina HT-12 v3 platform. This probe has a perfect quality score as 
no repeat regions were targeted by the probe. The Chi-square test was used for testing 
association between categorical variables and a multivariate Cox model was fitted to the data 
using breast cancer specific death as an endpoint. Recursive partitioning  was used to identify 
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a cut-off in gene expression values such that the resulting subgroups have significantly 
different survival courses. 
The external validation was done using bc-GenExMiner v3.0 (Breast Cancer Gene-
Expression Miner v3.0) online dataset (http://bcgenex.centregauducheau.fr) comprising 
previously published gene expression datasets from fifteen independent breast cancer studies 
totalling 2413 tumours  and summarized in supplementary Table S2. The bioinformatics tool 
is composed of two statistical mining modules. The first module is a "prognostic module", 
which offers the possibility to evaluate the in vivo prognostic informativity of genes of 
interest in breast cancer, and the second module is a "correlation module", which permits to 
compute correlation coefficients between gene expressions or to find lists of correlated genes 
in breast cancer. We used the prognostic module in this external validation. Statistical 
analyses were performed by means of survival statistical tests (Cox model, Kaplan–Meier 
and Forest plots). Supplementary Table S2 summarizes individual cohorts where BLM 
mRNA expression was investigated.                                                                                                                    
BLM protein expression in breast cancer: The study was performed in a consecutive series 
of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 
and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.  Patient 
demographics are summarised in Supplementary Table S3. This is a well-characterized series 
of patients with long-term follow-up that have been investigated in a wide range of biomarker 
studies (12-20).  All patients were treated in a uniform way in a single institution with 
standard surgery (mastectomy or wide local excision) with radiotherapy. Prior to 1989, 
patients did not receive systemic adjuvant treatment (AT). After 1989, AT was scheduled 
based on prognostic and predictive factor status, including Nottingham Prognostic Index 
(NPI), ER status, and menopausal status. Patients with NPI scores of <3.4 (low risk) did not 
receive AT. In pre-menopausal patients with NPI scores of ≥3.4 (high risk), classical 
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Cyclophosphamide, Methotrexate, and 5-Flurouracil (CMF) chemotherapy was given; 
patients with ER positive tumours were also offered endocrine therapy. Postmenopausal 
patients with NPI scores of ≥3.4 and ER positivity were offered endocrine therapy, while ER 
negative patients received classical CMF chemotherapy. Median follow up was 111 months 
(range 1 to 233 months).  Overall survival data was maintained on a prospective basis.   
Breast cancer specific survival (BCSS) was defined as the number of months from diagnosis 
to the occurrence of BC related-death. Survival was censored if the patient was still alive at 
the time of analysis, lost to follow-up, or died from other causes. We also evaluated 20 
tumour associated normal breast tissue for BLM expression. 
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (21), 
were followed throughout this study.  Ethical approval was obtained from the Nottingham 
Research Ethics Committee (C202313).  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from the centre and 
periphery of the tumours. The TMAs were immunohistochemically profiled for BLM and 
other biological antibodies (Supplementary Table S4) as previously described (12-20).  
Immunohistochemical staining was performed using the Thermo Scientific Shandon 
Sequenza chamber system (REF: 72110017), in combination with the Novolink Max Polymer 
Detection System (RE7280-K: 1250 tests), and the Leica Bond Primary Antibody Diluent 
(AR9352), each used according to the manufacturer’s instructions (Leica Microsystems).  
The tissue slides were deparaffinised with xylene and then rehydrated through five decreasing 
concentrations of alcohol (100%, 90%, 70%, 50% and 30%) for two minutes each. Pre-
treatment antigen retrieval was performed on the TMA sections using sodium citrate buffer 
(pH 6.0) and heated for 20 minutes at 95°C in a microwave (Whirpool JT359 Jet Chef 
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1000W). A set of slides were incubated for 18 hours with the primary anti-BLM antibody 
(NBP1-89929, Novus Biologicals, UK), at a dilution of 1:100. Negative and positive (by 
omission of the primary antibody and IgG-matched serum) controls were included in each 
run. The negative control ensured that all the staining was produced from the specific 
interaction between antibody and antigen. 
 
Evaluation of immune staining: The tumour cores were evaluated by two scorers (TAF and 
AA) and the concordance between the two scorer was excellent (k = 0.79). Whole field 
inspection of the core was scored and intensities of nuclear staining were grouped as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage 
of each category was estimated (0-100%).  Histochemical score (H-score) (range 0-300) was 
calculated by multiplying intensity of staining and percentage staining. A median H score of 
≥ 50 was taken as the cut-off for high BLM nuclear and cytoplasm expression. Not all cores 
within the TMA were suitable for IHC analysis as some cores were missing or lacked tumour 
(<15% tumour).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
hazard model. The proportional hazards assumption was tested using standard log-log plots. 
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. 
All tests were two-sided with a 95% CI and a p value < 0.05 considered significant.  For 
multiple comparisons, p values were adjusted according to Benjamini-Hochberg method (22).  
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Breast cancer cell lines and culture: MCF-7 (ER+/PR+/HER2-, BRCA1 proficient), MDA-
MB-231 (ER-/PR-/HER2-, BRCA1 proficient), MDA-MB-468 (ER-/PR-/HER2-, BRCA1 
proficient)  and MDA-MB-436 (ER-/PR-/HER2-, BRCA1 deficient) were used in the current 
study. All cell lines were purchased from ATCC and authenticated by ATCC. Cells were 
grown in RPMI (MCF-7, MDA-MB-231) or DMEM (MDA-MB-468 and MDA-MB-436) 
medium with the addition of 10% foetal bovine serum and 1% penicillin/streptomycin. Cell 
lysates were prepared and Western blot analysis performed.  Primary anti-BLM antibody 
(NBP1-89929, Novus Biologicals, and UK) was incubated over night at room temperature at 
a dilution of 1:1500. Primary anti-β actin antibody (1:10000 dilution [Abcam]) was used as a 
loading control. Infrared dye-labelled secondary antibodies (Li-Cor) [IRDye 800CW Mouse 
Anti-Rabbit IgG and IRDye 680CW Rabbit Anti-Mouse IgG] were incubated at a dilution of 
1:10000 for 1 hour.  Membranes were scanned with a Li-Cor Odyssey machine (700 and 
800nm) to determine protein expression.  
 
Quantitative real –time PCR: Total RNA was extracted from MCF-7, MDA-MB-231, 
MDA-MB-468 and MDA-MB-436 cells using RNeasy Mini kit (QIAGEN, UK). The 
quantification of the extracted RNA was done using a  NanoDrop 2000c Spectrophotometer 
(Thermo Scientific, UK). The cDNA was synthesized from 0.5 μg of total RNA using RT2 
first strand kit (QIAGEN, UK). qPCR was performed using SYBR Green PCR Master mix 
(applied biosystems,Warrington,UK) with primer set (BLM QuantiTect Prier Assay,Cat. No. 
QT00027671, QIAGEN) targeting BLM gene. The glyceraldehyde-3-phosphate 
dehydrogenase housekeeper gene was used as an internal control (GAPDH QuantiTect Prier 
Assay, Cat. No. QT00079247, QIAGEN). The real-time PCR for each RNA sample was 
performed in triplicate. NTC (No Template Control) was used to rule out cross contamination 
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of reagents and surfaces. NTC included all the RT-PCR reagents except the RNA template. 
Minus reverse transcriptase (- RT) control was used to rule out genomic DNA contamination. 
 
RESULTS 
 
High BLM transcript levels correlate to aggressive breast cancer 
 
BLM mRNA level was investigated in the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) cohort comprising 1980 breast tumours. High BLM mRNA 
expression was highly significantly associated with aggressive clinicopathological features 
(Table 1) including  high histological grade, larger tumour size, high-risk Nottingham 
prognostic index (NPI  >3.4), Her-2 over expression, ER negative, PR negative and triple 
negative phenotypes (ps<0.0001). High BLM mRNA expression was also found to be 
significantly associated with previously described molecular phenotypes in breast cancer: 
PAM50.Her2 (p<0.0001), PAM50.Basal (p<0.0001) and PAM50.LumB (p<0.0001), Genufu 
subtype (ER-/Her2-), Genufu subtype (ER+/Her2-/High proliferation) and Genufu subtype 
(Her2 positive) breast tumours. However, PAM50.LumA tumours and Genufu subtype 
(ER+/Her2-/low proliferation) were more likely to express low levels of BLM mRNA 
(ps<0.0001). Similarly, BLM mRNA level was significantly associated with the various 
biological subgroups [labelled integrative clusters (intClust) 1-10] described in the 
METABRIC study which was based on gene copy number changes and gene expression data 
(11).   High BLM mRNA expression was significantly associated with intClust.1 (p<0.0001), 
intClust.5 (p<0.0001), intClust.9 (p<0.0001) and intClust.10 (p<0.0001), which had the worst 
clinical outcome in the METABRIC study (11).  Low BLM mRNA expression was associated 
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with intClust.3 (p<0.0001), intClust.4 (p<0.0001), intClust.7 (p=0.003) and intClust.8 
(p<0.0001), which had intermediate to good prognosis in the METABRIC study (11).  
 
We then proceeded to survival analysis. High BLM mRNA expression in tumours was 
associated with adverse BCSS in the whole cohort (p<0.0001) (Figure 1A). In ER+ sub-
group, high BLM mRNA expression was associated with poor BCSS (p<0.0001) (Figure 1B). 
In the ER+ sub-group that received adjuvant endocrine therapy, high BLM mRNA expression 
remains associated with poor BCSS (p<0.0001) (Figure 1D).    In ER- sub-group, low BLM 
mRNA expression was associated with poor BCSS with borderline significance (p=0.049) 
(Figure 1C). In the ER- sub-group that received adjuvant chemotherapy, although there was a 
trend, BLM mRNA expression did not significantly influence outcome (p=0.062) (Figure 1E) 
and was most likely due to limited number of patients in this cohort (n=262). In multivariate 
Cox regression analysis that included other validated prognostic factors, such as lymph node 
stage, histological grade and tumour size ,  BLM  mRNA expression was a powerful 
independent predictor for breast cancer specific survival (p<0.00001) (Table 2). External 
validation was performed using bc-GenExMiner v3.0 (Breast Cancer Gene-Expression Miner 
v3.0) online dataset (http://bcgenex.centregauducheau.fr) comprising previously published 
gene expression datasets from fifteen independent breast cancer studies totalling 2413 
tumours and summarized in supplementary materials and Table S2. The dataset provides 
information on metastasis relapse (MR) free survival data. As shown in the Forest plot 
(Supplementary Figure S1) low BLM mRNA expression was significantly associated with 
better MR free survival (Supplementary Figure S1A and S1B). Taken together, the data 
provides the first compelling evidence that high BLM mRNA expression has prognostic 
and/or predictive significance in breast cancer.  
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Sub-cellular localisation of BLM protein is associated with aggressive breast cancer 
 
BLM is a 1417 amino acid protein with a highly conserved centrally located helicase domain. 
In addition, BLM has multiple domains involved in DNA- binding, ATPase activity and 
interaction with other binding partners. The nuclear localisation signal is present in the C-
terminal region of the protein (1-5). BLM is primarily expressed in late S/G2 phase of the cell 
cycle. Upon DNA damage BLM localises to the nucleus where it interacts with Rad51 and is 
intimately involved in HR repair that is operational during the S-phase of the cell cycle (23). 
In addition, BLM undergoes post translational modifications such as phosphorylation and 
SUMOylation that can affect intracellular localisation and biochemical activity (1-5). Besides 
a role in HR repair, BLM is also known to interact with key factors involved in base excision 
repair (BER) (e.g. FEN1) and non-homologous end joining pathway (NHEJ) (e.g. DNA-
PKcs) (1-5). Moreover, BLM also interacts with  important players in DNA- damage 
signalling and cell cycle regulation (ATM-Chk2 and ATR-Chk1 pathway), which ultimately 
dictate whether a cell initiates cell cycle arrest to allow DNA repair or proceed to apoptosis 
(1-5). We therefore investigated BLM protein expression in breast cancer and correlated to 
expression of other markers associated the DNA-damage signalling, NHEJ, BER, cell cycle 
regulation and apoptosis. 
 
We proceeded to evaluation of BLM protein expression in breast cancers. We initially 
profiled a panel of breast cancer cell lines. As shown in Supplementary Figure S2A; MDA-
MB-231, MDA-MB-436 and MDA-MB-468 breast cancer cells have robust expression of 
BLM protein. In contrast, MCF-7 has low BLM expression. At the mRNA level, MCF-7 cells 
have low BLM mRNA compared MDA-MB-231, MDA-MB-436 and MDA-MB-468 cells. 
The data demonstrates differential BLM expression across different breast cancer cell lines. 
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We then conducted immunohistochemical evaluation of BLM protein expression in the 
Nottingham Tenovus series comprising 1650 breast tumours. Surprisingly, we observed 
complex sub-cellular localization of BLM protein in breast cancers including tumours 
exhibiting nuclear staining only, cytoplasmic staining only, nuclear-cytoplasmic co-
expression or negative staining.  We also evaluated 20 tumour associated normal breast tissue 
for BLM expression. We observed strong nuclear staining in 19/20 normal breast tissue 
(mean H-score =235) (supplementary Figure S2B1). 1/20 did not show any nuclear BLM 
staining. No cytoplasmic staining was observed in any normal breast tissue. The data 
confirms that nuclear expression is a common feature of normal breast tissue and altered sub-
cellular localisation is a feature of breast tumours. 
 
Nuclear BLM protein level and breast cancer: Low nuclear BLM levels were seen in 54% 
of tumours (n= 682/1253) and high nuclear BLM levels were observed in 46% of tumours 
(n= 571/1253) (Supplementary Figure S2B4). As shown in supplementary table S5, low 
nuclear BLM level was significantly associated with larger tumours, high tumour grade, 
higher mitotic index, pleomorphism and tumour type (p<0.05). ER-, PR-, AR-, triple negative 
and basal-like phenotypes were more common in tumours with low nuclear BLM protein 
level (p<0.01). BRCA1 negative, low XRCC1, low FEN1, low SMUG1, low APE1, low 
Polβ, low ATR and low DNA-PKcs were significantly associated with tumours that have low 
nuclear BLM protein level. In addition, high p16, low p21, high MIB1, high p53, low Bcl-2, 
low Top2A, low nuclear pCHEK1 and low nuclear Chk2 were more common in tumours 
with low nuclear BLM protein level (p<0.05). 
 
Cytoplasmic BLM protein level and breast cancer: High cytoplasmic BLM levels were 
seen in 53% of tumours (n= 642/1212) and low cytoplasmic BLM levels were seen in 47% of 
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tumours (n= 570/1212) (Supplementary Figure S2B3). As shown in supplementary table S6, 
high cytoplasmic BLM level was significantly associated with pleomorphism, tumour type, 
high XRCC1, high FEN1, high APE1, high ATR, high DNA-PKcs, high MIB1, high Chk2, 
high Bax levels.   
 
Nuclear and cytoplasmic co-expression of BLM in breast cancer: 28% (333/1253) of 
tumours were low nuclear/high cytoplasmic, 26.5% (332/1253) were low nuclear/low 
cytoplasmic, 26.5% (333/1253) were high nuclear/high cytoplasmic and 19% (238/1253) 
were high nuclear/low cytoplasmic (Supplementary Figure S2B5).  Clinicopathological 
association are shown in Table 3 and supplementary Table S7. Tumours with high 
cytoplasmic/low nuclear BLM levels were more likely to be high grade, high mitotic index, 
pleomorphism, IDC-NST tumour type, PR-, triple negative and basal-like phenotype tumours 
(p<0.0001). High p16, low p21, high MIB1, high p53 and high Bax levels more common in 
tumours with high cytoplasmic/low nuclear BLM levels. We also correlated BLM co-
expression with various DNA repair factors and observed significant associations. BRCA1 
negativity was observed in 24.6% of BLM n-/c- tumours compared to 13.2% (BLM n+/c- 
tumours), 20.3% (BLM n-/c+ tumours) and 17.3% (BLM n+/c+ tumours). Similarly, BLM n-
/c- tumours  were more likely to exhibit low XRCC1 (25.6%), low FEN1 (83.8%), low 
SMUG1 (47.1%), low APE1 (66.8%), low pol β (50.9%), low ATR (75.9%) and DNA-PKcs 
(45.8%) compared to tumours that express  BLM n+/c-, BLM n-/c+, or BLM n+/c+  co-
expression (see Table 3).  
 
BLM and Rad51 protein co-expression in breast cancer: A key interacting partner of 
BLM is Rad51 (24). Together BLM-Rad51 play an essential role in HR repair (1-5). We 
therefore conducted exploratory nuclear co-expression studies in breast cancer.  As shown in 
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supplementary Table S8, we observed significant association between BLM-/Rad51- tumours 
and NPI>3.4, high grade, high mitotic index, pleomorphism, tumour type. Interestingly, ER 
negativity was observed in 47.1% of BLM-/RAD51- tumours compared to 30.5% 
(BLM+/RAD51- tumours), 30.9% (BLM-/RAD51+ tumours) and 17.9% in BLM+/RAD51+ 
tumours. Similarly, PR negativity was observed in 64.4% of BLM -/RAD51- tumours 
compared to 47.9% (BLM+/RAD51- tumours), 42.9% (BLM-/RAD51+ tumours) and 35.3% 
(BLM+/RAD51+ tumours) (see supplementary Table  S8).  
 
Survival analyses: In univariate analysis, in high risk ER positive tumours that received no 
endocrine therapy, patients whose tumours had high nuclear/low cytoplasmic BLM had poor 
BCSS (p=0.036) implying that altered expression has prognostic significance (Supplementary 
Figure S3). In patients who received endocrine therapy, although low nuclear/high 
cytoplasmic BLM tumours have the worst survival status in breast cancer, there was no 
statistical significance. Similarly in ER- tumours, BLM level did not significantly influence 
survival. When BLM (nuclear) and Rad51 (nuclear) were investigated together, BLM-
/Rad51- tumours have poor survival in the whole cohort and in the ER- sub-group that 
received adjuvant chemotherapy (Supplementary Figure S4). BLM/Rad51 expression did not 
influence survival in ER + tumours (Supplementary Figure S5). In multivariate analysis 
(Supplementary Table S9), nuclear BLM level independently influenced survival (p=0.026). 
Tumour stage, grade and HER-2 expression were other factors independently associated with 
breast cancer specific survival.    
 
DISCUSSION 
DNA helicases are molecular motors that unwind DNA, a process that is required during 
DNA replication, DNA repair and telomere maintenance. RecQ family of DNA helicases 
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includes RECQL1, RECQL4, RECQL5, WRN and BLM. The critical role played by RecQ 
family of DNA helicases in genomic stability is underpinned by the fact that germ-line 
mutations in these genes result in genetic disorders characterised by premature aging and/or 
predisposition to cancers (1-5). RecQ helicases may also have a role in the pathogenesis of 
sporadic cancers. RECQL4 has been shown to be involved in prostate carcinogenesis (1-5). 
RECQL1 genetic polymorphisms have been linked to pancreatic cancer and RECQL1 
overexpression has been demonstrated in head & neck and brain tumours (1-5). In the current 
study, we have comprehensively investigated the role of BLM in breast cancer. We provide 
compelling evidence that high BLM mRNA expression is a strong prognostic and predictive 
biomarker in breast cancer. High BLM mRNA was linked to aggressive clinicopathological 
phenotypes. High BLM mRNA was associated with aggressive molecular phenotypes 
including PAM50. Luminal B, PAM50. Her2 and PAM50. basal molecular phenotypes. 
Given the role of BLM during replication and proliferation (25), it is perhaps not surprising 
that high BLM mRNA was more frequent in aggressive breast cancers. To further support this 
hypothesis we also observed that low BLM mRNA expression was more common in PAM50. 
Lumina A and ER+/Her-2 negative/low proliferation Genefu subtype tumours. Interestingly, 
BLM mRNA levels are also linked to biologically distinct integrative clusters reported in the 
METABRIC study (11). High BLM mRNA level was frequent in intClust 10 subgroup which 
is the most highly genomically unstable sub group with basal-like features.  Low BLM  
mRNA level was seen in intClust 3 subgroup that is characterised by low genomic instability. 
Together the data suggest that BLM mRNA level may also inform genomic stability status in 
breast. In addition, high BLM mRNA level is also frequently seen in intClust 5 (HER-2 
enriched with worst survival), intClust 9 (8q cis-acting/20qamplified mixed subgroup), and 
intClust 1 (17q23/20q cis-acting luminal B subgroup) subgroups that also manifest an 
aggressive phenotype. On the other hand, low BLM mRNA level is linked to  intClust 4 
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(includes both ER-positive and ER-negative cases with a flat copy number landscape and 
termed the ‘CNA-devoid’ subgroup with extensive lymphocytic infiltration), intClust 7 (16p 
gain/16q loss with higher frequencies of 8q amplification luminal A subgroup) and intClust 8 
subgroups (classical 1q gain/16q loss luminal A subgroup) (11). Of note, the data presented 
here is strikingly similar to the clinicopathological associations we recently reported for 
FEN1 (flap endonuclease 1), a key player in long-patch base excision repair and DNA 
replication, in the METABRIC cohort (15). Interestingly, BLM has been shown to stimulate 
FEN1 activity in a preclinical study (26). The functional interaction appeared to be 
independent of BLM helicase activity in that study (26).  
 
At the protein level, low nuclear and/or high cytoplasmic expression was associated with 
aggressive phenotypes. Association with high cytoplasmic expression was surprising.  In 
contrast, normal breast tissue showed only strong nuclear staining and no cytoplasmic 
staining. As cytoplasmic function of BLM has not been described previously, we speculate 
that cytoplasmic accumulation in a proportion of breast tumours probably reflects 
dysregulation of mechanisms involved in nuclear localization of BLM. Cytoplasmic 
accumulation along with low nuclear BLM expression could then increase genomic 
instability in tumours and promote a mutator phenotype characterised by aggressive biology. 
To support this hypothesis we observed that low nuclear BLM levels with or without 
cytoplasmic expression were more likely to be high grade, high mitotic index, pleomorphism, 
IDC-NST tumour type, PR-, triple negative and basal-like phenotype tumours. In addition, 
low nuclear BLM with or without cytoplasmic expression was also associated with impaired 
expression of other DNA repair factors including BRCA1 negativity, low XRCC1, low 
FEN1, low SMUG1, low APE1, low Polβ, low ATR and low DNA-PKcs. Moreover, in 
multivariate analysis, nuclear BLM level independently influenced survival. As BLM and 
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Rad51 are known to interact with each other for efficient HR repair (24), we also performed 
BLM-Rad51 co-expression studies. As expected, low nuclear BLM/low nuclear RAD51 
tumours exhibited aggressive phenotype and associated with poor survival.   In a previous 
small study in normal and neoplastic human cells, BLM protein expression was shown to be 
overexpressed in a panel of tumour tissue compared to normal tissue including a cohort of 
nine breast tumours (27). Similar to our study, the authors observed a positive correlation 
between BLM and Ki67 but did not report any clinicopathological associations (27). Another 
interesting observation in the current study was that although BLM mRNA overexpression 
was categorically associated with aggressive tumours and poor outcomes, at the protein level, 
the association appeared more complex with low nuclear BLM protein level or low 
nuclear/high cytoplasmic BLM protein level being associated with adverse features. We 
speculate that either BLM mRNA is subjected to post-transcriptional regulation or post 
translational dysregulation of BLM protein expression/sub-cellular localization could in turn 
affect BLM mRNA expression through feedback loops. Detailed mechanistic studies are 
therefore required to understand the regulation of BLM in vivo.  Data presented in the current 
study also suggest that BLM could be a promising marker for personalization of therapy. As 
low BLM is a marker of impaired HR repair, we would argue that low BLM tumours could 
be targeted by synthetic lethality using inhibitors of base excision repair such as those 
targeting PARP (28). Alternatively high BLM tumours could be targeted by small molecular 
inhibitors of BLM that are currently under development (10).  In conclusion we provide the 
first clinical evidence that BLM is a promising biomarker and a rational drug target in breast 
cancer. 
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Table 1: Association between BLM mRNA expression and clinico-pathologic variables in METABRIC cohort. 
 
 
Variable 
 
 
BLM mRNA Expression 
 
 
 P Values 
Low 
(n=763) 
High 
(n=1208) Unadjusted Adjusted* 
N (%) N (%) 
 
A) Pathological    Parameters
Lymph node stage  
Negative 434(56.9%) 601(49.8%) 0.003 
 
0.0034 
 Positive (1-3) 100(13.1%) 214(17.7%) 
Positive (>3) 229(30.0%) 393(32.5%) 
Grade 
G1 124(17.3%) 45(3.8%) 1.9X10-63 1.0X10-5 
G2 404(56.3%) 366(31.3%) 
G3 190(26.5%) 760(64.9%) 
Tumour Size (cm) 
T 1a+b(1.0) 49(6.4%) 43(3.6%) 1.4X10-5 1.0X10-5 
T 1c(>1.0-2.0) 334(43.9%) 432(36.1%) 
T2 (>2.0-5) 341(44.9%) 660(55.1%) 
T3 (>5) 36(4.7%) 62(5.2%) 
NPI 
≤ 3.4 385(50.3%) 295(24.3%) 2.2X10-32 1.0X10-5 
>3.4 380(49.7%) 917(75.7%) 
 
Her2 overexpression (No)  733(95.8%) 999(82.4%) 1.3X10-18 1.0X10-5 
                                  (Yes ) 32(4.2%) 213(17.6%) 
Triple negative          (No)        731(95.6) 929 (76.7) 6.5X10-29 1.0X10-5 
                                  (Yes)  34(4.4) 283(23.3) 
ER                       (Negative) 55(7.2%) 415(34.2%) 4.3X10-43 1.0X10-5
                            (Positive) 710(92.8%)  797(65.8%) 
PR                       (Negative) 223(29.2%) 713(58.8%) 6.4X10-38 1.0X10-5 
                            (Positive) 542(70.8%) 499(41.2%) 
Genefu subtype 
ER-/Her-2 negative 20(5.1%) 130(21.5%) 2.2X10-12 1.0X10-5
ER+/Her-2 negative/high proliferation 71(18.3%) 295(48.8%) 2.2X10-22 1.0X10-5 
ER+/Her-2 negative/low proliferation 283(72.8%) 85(14.0%) 4.4X10-78 1.0X10-5 
Her-2 positive 15(3.9%) 95(15.7%) 6.2X10-9 1.0X10-5
PAM50 subtype 
PAM50.Her2 33(5.2%) 205(18.0%) 3.8X10-14 1.0X10-5 
PAM50.Basal   19(3.0%) 311(27.3%)  2.2X10-36 1.0X10-5
PAM50.LumA 483(76.2%) 232(20.4%)  8.1X10-117 1.0X10-5
PAM50.LumB 98(15.5%) 391(34.3%) 1.7X10-17 1.0X10-5
IntClust subgroups 
intClust.1 21(2.7%) 116(9.6%) 5.8X10-9 1.0X10-5 
intClust.2 20(2.6%) 52(4.3%) 0.053 0.055 
intClust.3  203(26.5%) 87(7.2%) 2.1X10-32 1.0X10-5
intClust.4 191(25.0%) 152(12.5%) 1.2X10-12 1.0X10-5
intClust.5 21(2.7%) 168(13.9%) 2.6X10-16 1.0X10-5
intClust.6 27(3.5%) 59(4.9%) 0.155 4.03 
intClust.7 92(12.0%) 97(8.0%) 0.003 0.003 
intClust.8 156(20.4) 144(11.9%) 2.7X10-7 1.0X10-5
intClust.9 28(3.7%) 118(9.7%)   4.8X10-7 1.0X10-5
intClust.10 6(0.8%) 219(18.1%) 4.5X10-32 1.0X10-5
Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone 
receptor;Triple negative: ER-/PgR-/HER2-. *Adjusted p values were calculated using Benjamini-Hochberg method to adjust for multiple 
testing. 
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Table 2: Multivariate analysis in the METABRIC cohort confirms that BLM mRNA over expression is a powerful 
independent prognostic factor. 
 P-Value HR 95% CI for HR 
Lower Upper 
Breast Cancer Specific Survival 
BLM mRNA expression 2.0x10-6 1.523 1.278 1.815 
Size  1.0x10-6 1.112 1.068 1.158 
Grade 
G1 
G2 
G3 
 
 
0.121 
0.0044 
 
1.0 
1.782 
2.03 
 
 
1.094 
1.241 
 
 
2.903 
3.321 
LN Status 
LN (1-3) 
LN(>3) 
 
0.21 
1.0x10-6 
 
1.697 
3.646 
 
1.367 
2.890 
 
2.108 
4.601 
 
Bold: Statistically significant; HR: Hazard Ratio; CI: Confidence interval; LN: Lymph node 
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Table 3. BLM (nuclear and cytoplasmic protein co-expression) in breast cancer 
  
   
 
                    VARIABLE 
 
BLM  Protein Expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) Nuc-/Cyto- 
( n= 332) 
N (%) 
Nuc+/Cyto- 
(n=360) 
N (%) 
Nuc-/Cyto+ 
(n=353) 
N (%) 
 
Nuc+/Cyto+ 
(n=333) 
N (%) 
 
Tumour Grade                              
 G1 
 G2 
 G3 
 
53 (16.0) 
87 (26.2) 
192 (57.8) 
 
52 (21.8) 
208 (42.0) 
86 (36.1) 
 
45 (12.9) 
102 (29.1) 
203 (58.0) 
 
59 (17.7) 
108 (32.4) 
166 (49.8) 
 
3.0X10-6 
 
1.0X10-5 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
93 (28.4) 
65 (19.8) 
170 (51.8) 
  
117 (49.4) 
39 (16.5) 
81 (34.2) 
 
91 (26.1) 
64 (18.3) 
194 (55.6) 
 
129 (38.9) 
55 (16.6) 
148 (44.6) 
 
1.0X10-6 
 
1.0X10-5 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
12 (3.7) 
112 (34.1) 
204 (62.2) 
 
6 (2.5) 
122 (51.5) 
109 (46.0) 
 
2 (0.6) 
119 (34.2) 
227 (65.2) 
 
8 (2.4) 
114 (34.4) 
209 (63.1) 
 
1.2X10-5 
 
1.0X10-5 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
170 (59.2) 
55 (19.2) 
12 (4.2) 
28 (9.8) 
22 (7.7) 
 
105 (53.3) 
39 (19.8) 
0 (0.0) 
30 (15.2) 
23 (11.7) 
 
204 (65.2) 
59 (18.8) 
12 (3.8) 
17 (5.4) 
21 (6.7) 
 
170 (58.2) 
66 (22.6) 
3 (1.0) 
18 (6.2) 
35 (12.0) 
 
6.6X10-5 
 
1.0X10-4 
Triple Negative Phenotype               
No 
Yes 
 
244 (74.8) 
82 (25.2) 
 
210 (89.4) 
25 (10.6) 
 
248 (73.2) 
91 (26.8) 
 
285 (88.5) 
37 (11.5) 
 
1.0X10-6 
 
1.0X10-5 
ER               
Negative 
Positive 
 
110 (33.5) 
218 (66.5) 
 
40 (16.9) 
197 (83.1) 
 
112 (32.7) 
231 (67.3) 
 
68 (20.6) 
262 (79.4) 
 
1.0X10-6 
 
1.0X10-5 
BRCA1                     
Absent 
 Normal 
 
59 (24.6) 
181 (75.4) 
 
20 (13.2) 
131 (86.8) 
 
52 (20.3) 
204 (79.7) 
 
41 (17.3) 
196 (82.7) 
 
 
0.036 
 
0.047 
XRCC1                             
Low 
High 
 
61 (25.6) 
177 (74.4) 
 
23 (12.8) 
156 (87.2) 
 
27 (11.6) 
205 (88.4) 
 
153 (16.7) 
761 (83.3) 
 
1.7X10-4 
 
3.0X10-4 
FEN1                   
Low 
High 
 
192 (83.8) 37 
(16.2) 
 
117 (69.6) 
51 (30.4) 
 
169 (74.1) 
59 (25.9) 
 
152 (65.8) 
79 (34.2) 
 
1.0X10-4 
 
2.0X10-4 
SMUG1                  
Low 
High 
 
104 (47.1) 
117 (52.9) 
 
 
51 (33.3) 
102 (66.7) 
 
73 (34.4) 
139 (65.6) 
 
77 (35.5) 
140 (64.5) 
 
0.013 
 
0.018 
APE1 
Low 
High 
 
185 (66.8) 
92 (33.2) 
 
93 (44.7) 
115 (55.3) 
 
99 (35.0) 
184 (65.0) 
 
532 (49.7) 
538 (50.3) 
 
1.0X10-6 
 
1.0X10-5 
Polβ 
Low 
High 
 
 
147 (50.9) 
142 (49.1) 
 
56 (25.9) 
160 (74.1) 
 
130 (42.1) 
179 (57.9) 
 
91 (30.6) 
206 (69.4) 
 
1.0X10-6 
 
1.0X10-5 
ATR 
Low 
High 
 
236 (75.9) 
75 (24.1) 
 
146 (69.5) 
64 (30.5) 
 
221 (67.4) 
107 (32.6) 
 
175 (55.6) 
140 (44.4) 
 
1.0X10-6 
 
1.0X10-5 
DNA-PKcs 
Low 
High 
 
126 (45.8) 
149 (54.2) 
 
58 (29.4) 
139 (70.6) 
 
124 (41.5) 
175 (58.5) 
 
68 (23.3) 
224 (76.7) 
 
1.0X10-6 
 
1.0X10-5 
MIB1                       
Low 
High 
 
121 (44.5) 
151 (55.5) 
 
117 (57.6) 
86 (42.4) 
 
106 (37.7) 
175 (62.3) 
 
127 (44.9) 
156 (55.1) 
 
 
4.2X10-5 
 
1.0X10-4 
P53              
Low expression 
High expression 
 
214 (78.1) 
60 (21.9) 
 
156 (85.2) 
27 (14.8) 
 
206 (72.0) 
80 (28.0) 
 
225 (80.9) 
53 (19.1) 
 
0.005 
 
0.008 
Bcl-2                            
Negative 
Positive 
 
119 (40.3) 
176 (59.7) 
 
56 (27.5) 
148 (72.5) 
 
127 (27.5) 
148 (72.5) 
 
99 (32.8) 
203 (67.2) 
 
 
0.006 
 
0.009 
TOP2A                    
Low 
Overexpression 
 
129 (56.6) 
99 (43.4) 
 
64 (39.8) 
97 (60.2) 
 
110 (43.1) 
145 (56.9) 
 
98 (41.4) 
139 (58.6) 
 
0.001 
 
0.002 
Bold = statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; 
CK: cytokeratin; Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER-/PgR-/HER2- . Adjusted p values were calculated 
using Benjamini-Hochberg false discovery rate method to adjust for multple testing. *Fischer test was used to obtain p values where one or more of cells has an expected 
frequency of five or less.  For full data please also see supplementary Table S 
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FIGURE LEGENDS 
                                                                                                                                                                   
Figure 1: Kaplan Meier curves showing BCSS (Breast cancer specific survival) based on BLM mRNA expression 
in A. whole cohort; B. ER+ cohort; C. ER- cohort; D. ER+ patients with NPI >3.4, who received endocrine therapy 
and E. ER- patients with NPI >3.4, who received chemotherapy. 
 
BLM mRNA Expresion in Whole Cohort 
Low BLM (n=765) 
High BLM (n=1212) 
Log Rank =70.687 ; P = 4.1x10-17 
 
BLM mRNA Expression in ER+ Cohort 
High BLM (n=502) 
Low BLM (n=995) 
Log Rank = 62.169; P = 3.1x10-15 
BLM mRNA Expression in ER- cohort  
High BLM (n=99) 
Low BLM (n=339) 
Log Rank =3.865 ; P = 4.9 x10-3 
ER+; NPI>3.4; had endocrine therapy 
High BLM (n=605) 
Low BLM (n=498) 
Log Rank = 38.576 ; P = 5.2X10-10 
ER-; NPI>3.4; had chemotherapy 
High BLM (n=167) 
Low BLM (n=105) 
Log Rank = 3.485; P = 0.062 
A B C 
D E 
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Supplementary Table S1:  Clinicopathological characteristics in the METABRIC cohort  
Variables N (%) 
Age at diagnosis [Median (range)] 61.8 (21.93-96.29) 
Tumour size [Median (range)] 23 (1, 182) 
NPI [Median (95% CI)] 4.04 (3.99-4.09) 
Survival [Median (Months, 95% Cl)] 149 (141-159) 
Lymph nodes status 
 
0 
1 
2 
3 
>3 
 
 
 
1012 
336 
170 
112 
316 
ER status 
 
Positive 
Negative 
 
 
 
1485 
437 
PAM50 subtype 
 
Basal  
HER2  
Luminal A  
Luminal B  
 
 
322 
238 
714 
484 
Normal  
Not classified 
 
188 
6 
Adjuvant systemic therapy (AT)  
No AT  290 
Hormone therapy (HT) 1014 
Chemotherapy 226 
Hormone + chemotherapy 192 
 
  
Supplementary Table S2: External validation cohorts (pooled n = 2413). 
Study Code Reference* Number  of 
patients 
Number with 
Metastatic 
Relapse 
Rosetta2002 Van de Vijver et al.,2002 
[1]  
295 101 
PNAS1732912
100 
Sotiriou et al., 2003 [2] 99 30 
GSE2603 Minn et al., 2005 [3] 82 27 
GSE1456 Pawitan et al., 2005 [4] 159 40 
GSE2034 Wang et al., 2005 [5] 286 107 
GSE2741 Weigelt et al., 2005 [6] 88 20 
E_TABM_ Chin et al., 2006 [7] 112 21 
GSE7390 Desmedt et al., 2007 [8] 198 62 
GSE6532 Loi et al., 2007 [9] 393 101 
GSE5327 Minn et al., 2007 [10] 58 11 
GSE7849 Anders et al., 2008 [11] 75 14 
GSE9893 Chanrion et al., 2008 [12] 155 48 
GSE9195 Loi et al., 2008 [13] 77 10 
GSE11121 Schmidt et al., 2008 [14] 200 46 
GSE12093 Zhang et al., 2009 [15] 136 20 
Total:  2413 658 
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Supplementary Table S3: Clinicopathological characteristics of Nottingham cohort 
Variable n* Cases          (%) 
Menopausal status 1650  
Pre-menopausal  612          (37.0) 
postmenopausal  1038        (63.0) 
Tumour Grade (NGS) 1650  
G1   306          (18.5) 
G2  531          (32.2) 
G3   813          (49.3) 
Lymph node stage 1650  
Negative   1056         (64.0) 
Positive (1-3 nodes)  486          (29.5) 
Positive (>3 nodes)  108           (6.5) 
Tumour size (cm) 1650  
T1 a + b (≤1.0)  187         (11.0) 
T1 c (>1.0 -2.0)  868         (53.0) 
T2 (>2.0-5)  579      (35.0) 
T3 (>5)  16         (1.0) 
Tumour type 1650  
IDC-NST  941         (57) 
Tubular   349         (21) 
ILC  160        (10) 
Medullary (typical/atypical)  41          (2.5) 
Others  159        (9.5) 
NPI subgroups 1650  
Excellent PG(2.08-2.40) Low risk 207         (12.5) 
Good PG(2.42-3.40) 331          (20.1) 
Moderate I PG(3.42 to 4.4) High risk 488         (29.6) 
Moderate II PG(4.42 to 5.4) 395         (23.9) 
Poor PG(5.42 to 6.4) 170         (10.3) 
Very poor PG(6.5–6.8) 59         (3.6) 
Survival at 20 years 1650  
Alive and well  1055         (64.0) 
Dead from disease  468          (28.4) 
Dead from other causes  127         (7.6) 
Adjuvant systemic therapy (AT)   
No AT   665         (42.0) 
Hormone therapy (HT)  642         (41.0) 
Chemotherapy  307         (20.0) 
Hormone + chemotherapy  46         (3.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
 
Supplementary Table S4: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker 
Antigen Antibody Clone Source Antigen Retrieval 
Dilution /  
Incubation 
Time 
Distribution 
Scoring 
system 
Cut-offs 
BRCA1 BRCA1 MS110 Calbiochem Citrate pH6 
1:100 
60 min 
Nuclear % of positive cells 
 
<25% (negative) 
 
ATR 
Mouse 
MAb Anti-
ATR 
1E9 Novus Biologicals Citrate pH6 
1:20 
18 hours 
Nuclear H-score ≥60 (High) 
pChk1 Rabbit anti-pChk1 Ab58567 Abcam Citrate pH6 
1:140 
60 min 
Nuclear H-score ≥50 (High) 
DNA-PKcs Mouse MAb Anti- 3H6 Abcam Citrate pH6 
1:1000 
20 min 
Nuclear H-score >260 (high) 
 
XRCC1 
 
Mouse 
MAb Anti-
XRCC1 
 
33-2-5 
 
Thermo-
scientific 
 
Citrate pH6 
 
1:200 
20 min 
 
Nuclear 
 
% of positive 
cells 
 
≥10% (positive) 
APE1 Rabbit anti-APE-1 polyclonal 
Novus 
Biologicals Citrate pH6 
1:500 
60 min 
Nuclear H-score >100 (positive) 
SMUG1 Goat anti-SMUG1 polyclonal 
Acris 
Antibodies Citrate pH6 
1:200 
15 min 
Nuclear H-score ≤35 (negative) 
FEN1 Rabbit anti-FEN1 polyclonal 
Novus 
Biologicals Citrate pH6 
1:200 
60 min 
Nuclear  and 
Cytoplasm H-score ≤100 (negative) 
Rad51 Mouse anti-Rad51 polyclona Abcam Citrate pH6 
1:70 
60 min 
Nuclear H-score ≥10 (positive) 
P21 
Mouse 
MAb anti-
p21 
SW118 Dako-Cytomation Citrate pH6 
1:50 
60 min 
Nuclear % of positive cells ≥10% (positive) 
       Ki67 Mouse 
MAb anti-
Ki-67 
      MIB1 Dako-
Cytomation 
Citrate pH6 1:300 
60 min 
Nuclear % of positive 
cells 
< 10% (low) 
10-30% 
(moderate) 
>30% (high) 
P53 
Mouse 
MAb anti 
p53 
DO7 Novocastra Citrate pH6 
1: 50 
60 min 
Nuclear % of positive cells 
≤20% (negative) 
>20% (High) 
Bcl-2 
Mouse 
MAb anti-
Bcl2 
124 Dako-Cytomation Citrate pH6 
1:100 
60 min 
Cytoplasm % of positive cells >10% (positive 
ER 
Mouse 
MAb anti-
ER-α 
SP1 Dako-Cytomation Citrate pH6 
1:150 
30 min 
Nuclear Allred score ≥3 (positive) 
ER 
Mouse 
MAb anti-
ER-α 
EP1 Dako-Cytomation Citrate pH6 
1:80 
30 min 
Nuclear % positive cells ≥1% positive 
PR 
Mouse 
MAb anti-
PR 
PgR636 Dako-Cytomation Citrate pH6 
1:125 
30 min 
Nuclear % positive cells ≥1% positive 
CK14 
Mouse 
MAb anti-
Ck14 
LL002 Novocastra Citrate pH6 
1:40 
60 min 
Cytoplasm % of positive cells ≥10% (positive) 
Ck5/6 
Mouse 
MAb anti-
Ck5/6 
D5/161B4 Dako-Cytomation EDTA pH8 
1:100 
60 min 
Cytoplasm % of positive cells ≥10% (positive) 
Ck17 
Mouse 
MAb anti-
Ck17 
E3 Dako-Cytomation Citrate pH6 
1:100 
60 min 
Cytoplasm % of positive cells ≥10% (positive) 
Ck18 
Mouse 
MAb anti-
Ck18 
DC10 Dako-Cytomation Citrate pH6 
1:100 
60 min 
Cytoplasm % of positive cells ≥10% (positive) 
HER2 
Rabbit 
antihuman 
c-erbB2 
polyclonal Dako-Cytomation None 
1:400 
60 min 
Membrane See text See text 
 
TOP2A 
 
Mouse 
MAb 
 
 
KiS1 
 
Dako-
Cytomation 
 
Citrate pH6 
 
 
1:150 
60 min 
 
Nuclear/ 
cytoplasm 
 
% of positive 
cells 
 
>25% (positive) 
 
All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (pH 6) except for HER2 (no pre-treatment) and EGFR (pre-treated with protease for 10 minutes).   
Supplementary Table S5: BLM (nuclear protein expression) in breast cancer   
   
 
                    VARIABLE 
 
BLM (Nuclear)  Protein Expression 
                   
 
 
Unadjusted 
   P- values 
 
 
*Adjusted  
P -Values Low 
(n=683) 
N (%) 
 
High 
(n=574) 
N (%) 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 50 (7.3) 
345 (50.6) 
265 (38.9) 
22 (3.2) 
 
67 (11.7) 
283 (49.6) 
213 (37.3) 
8 (1.4) 
 
0.012 
 
0.018 
Tumour Stage                                
1 
2 
3 
 
 
422 (61.8) 
198 (29.0) 
63 (9.2) 
 
356 (62.2) 
168 (29.4) 
48 (8.4) 
 
0.874 
 
36.70 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
98 (14.4) 
189 (27.7) 
395 (57.9) 
 
111 (19.4) 
208 (36.4) 
252 (44.1) 
 
7.0X10-6 
 
1.0X10-5 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
184 (27.2) 
129 (19.1) 
364 (53.8) 
  
246 (43.2) 
94 (16.5) 
229 (40.2) 
 
1.0X10-6 
 
1.0X10-5 
Tubule Formation                         
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
34 (5.0) 
219 (32.3) 
424 (62.6) 
 
34 (6.0) 
201 (35.3) 
334 (58.7) 
 
0.348 
 
0.365 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
14 (2.1) 
231 (34.2) 
431 (63.8) 
 
12 (1.5) 
236 (41.5) 
318 (56.0) 
 
0.020 
 
0.029 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
374 (62.3) 
114 (19.0) 
24 (4.0) 
45 (7.5) 
43 (7.2) 
 
275 (56.2) 
105 (21.5) 
3 (0.6) 
48 (9.8) 
58 (11.9) 
 
1.2X10-4 
 
4.0X10-4 
Lymphovascular Invasion            
No 
Yes 
 
454 (67.6) 
218 (32.4) 
 
362 (64.0) 
204 (36.0) 
 
0.183 
 
0.207 
B) Aggressive phenotype 
 
 
Her2 overexpression                     
No 
Yes 
 
603 (89.9) 
68 (10.1) 
 
487 (87.7) 
68 (12.3) 
 
0.240 
 
0.265 
Triple Negative Phenotype           
No 
Yes 
 
492 (74.0) 
173 (26.0) 
 
495 (88.9) 
62 (11.1) 
 
1.0X10-6 
 
1.0X10-5 
Basal Like Phenotype           
No 
Yes 
 
527 (82.7) 
110 (17.3) 
 
503 (92.0) 
44 (8.0) 
 
3.0X10-6 
 
1.0X10-5 
Cytokeratin 6 (CK6)                     
Negative 
Positive 
 
475 (80.4) 
116 (19.6) 
 
416 (88.1) 
56 (11.9) 
 
0.001 
 
0.002 
Cytokeratin 14 (CK14)                 
Negative 
Positive 
 
499 (85.3) 
86 (14.7) 
 
419 (89.7) 
48 (10.3) 
 
0.033 
 
0.042 
Cytokeratin 18 (CK18)                 
Negative 
Positive 
 
84 (15.4) 
460 (84.6) 
 
 
19 (4.4) 
411 (95.6) 
 
1.0X10-6 
 
1.0X10-5 
Cytokeratin 19 (CK19)                 
Negative 
Positive 
 
46 (7.8) 
545 (92.2) 
 
20 (4.3) 
446 (95.7) 
 
0.020 
 
0.028 
C) Hormone receptors 
 
 
 
ER               
Negative 
Positive 
 
222 (33.1) 
449 (66.9) 
 
108 (19.0) 
459 (81.0) 
 
1.0X10-6 
 
1.0X10-5 
PgR                                   
Negative 
Positive 
 
307 (47.8) 
335 (52.2) 
 
202 (38.5) 
323 (61.5) 
 
0.001 
 
0.002 
AR                     
Negative 
Positive 
 
 
248 (44.5) 
309 (55.5) 
 
123 (28.0) 
316 (72.0) 
 
1.0X10-6 
 
1.0X10-5 
D) DNA Repair 
 
 
BRCA1                     
Absent 
 Normal 
 
111 (22.4) 
385 (77.6) 
 
61 (15.7) 
327 (84.3) 
 
0.013 
 
0.019 
XRCC1                             
Low 
High 
 
103 (20.5) 
400 (79.5) 
 
50 (12.2) 
361 (87.8) 
 
0.001 
 
0.002 
FEN1                   
Low 
High 
 
361 (79.0) 
96 (21.0) 
 
269 (67.4) 
130 (32.6) 
 
1.0X10-5 
 
3.0X10-4 
SMUG1                  
Low 
High 
 
 
177 (40.9) 
256 (59.1) 
 
 
128 (34.6) 
242 (65.4) 
 
0.067 
 
0.082 
APE1 
Low 
High 
 
340 (58.7) 
239 (41.3) 
 
192 (39.1) 
299 (60.9) 
 
1.0X10-6 
 
1.0X10-5 
PolB 
Low 
High 
 
 
277 (46.3) 
321 (53.7) 
 
147 (28.7) 
366 (71.3) 
 
1.0X10-6 
 
1.0X10-5 
ATR  
Low 
High 
 
35 (6.1) 
538 (93.9) 
 
18 (3.9) 
449 (96.1) 
 
1.8X10-4 
 
5.0X10-4 
ATM  
Low 
High 
 
223 (52.0) 
206 (48.0) 
 
179 (53.8) 
154 (46.2) 
 
0.627 
 
0.642 
DNA-PK  
Low 
High 
 
250 (43.6) 
324 (56.4) 
 
126 (25.8) 
363 (74.2) 
 
1.0X10-6 
 
1.0X10-5 
E) Cell cycle/apoptosis regulators 
 
 
P16 
Low 
High 
 
396 (80.8) 
94 (19.2) 
 
347 (93.8) 
23 (6.2) 
 
1.0X10-6 
 
1.0X10-5 
P21 
Low 
High 
 
316 (60.5) 
206 (39.5) 
 
202 (53.2) 
178 (46.8) 
 
0.027 
 
0.036 
MIB1                       
Low 
High 
 
227 (41.0) 
326 (59.0) 
 
244 (50.2) 
242 (49.8) 
 
0.003 
 
0.006 
P53              
Low expression 
High expression 
           
 
420 (75.0) 
140 (25.0) 
 
381 (82.6) 
80 (17.4) 
 
0.003 
 
0.005 
Bcl-2                            
Negative 
Positive 
 
246 (40.2) 
366 (59.8) 
 
155 (30.6) 
351 (69.4) 
 
0.001 
 
0.002 
TOP2A                    
Low 
Overexpression 
 
 
239 (49.5) 
244 (50.5) 
 
162 (40.7) 
236 (59.3) 
 
0.009 
 
0.015 
pCHK1 (Nuclear)                       
Low 
High 
 
616 (90.2) 
67 (9.8) 
 
415 (72.3) 
159 (27.7) 
 
1.0X10-6 
 
1.0X10-5 
pCHK1 (Cytoplasmic)                  
Low 
High 
 
191 (28.0) 
492 (72.0) 
 
124 (21.6) 
450 (78.4) 
 
0.010 
 
0.016 
Non-phospho CHK1 (Cyto.)         
Low 
High 
 
284 (52.0) 
262 (48.0) 
 
205 (45.2) 
249 (54.8) 
 
0.031 
 
0.041 
CHK2                       
Low 
High 
 
258 (50.5) 
253 (49.5) 
 
164 (41.0) 
236 (59.0) 
 
0.004 
 
0.007 
Bax                         
Low 
High 
 
272 (68.9) 
123 (31.1) 
 
235 (72.1) 
91 (27.9) 
 
0.345 
 
0.371 
CDK1                            
Low 
High 
 
 
303 (67.2) 
148 (32.8) 
 
247 (72.0) 
96 (28.0) 
 
0.144 
 
0.172 
CDK18 (Cytoplasmic)                   
Low 
High 
 
426 (78.5) 
117 (21.5) 
 
318 (70.7) 
132 (29.3) 
 
0.005 
 
0.008 
RECQL5                  
Low 
High 
 
295 (56.0) 
232 (44.0) 
 
167 (36.9) 
285 (63.1) 
 
1.0X10-6 
 
1.0X10-5 
MDM2                          
Low 
Overexpression 
 
386 (77.4) 
113 (22.6) 
 
272 (73.3) 
99 (26.7) 
 
0.170 
 
0.198 
Bold = Statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human epidermal 
growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; 
Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER-
/PgR-/HER2- . *Adjusted p values were calculated using Benjamini-Hochberg method to adjust for 
multiple testing. 
  
Supplementary Table S6: BLM (cytoplasmic protein expression) in breast cancer  
   
 
                    VARIABLE 
 
BLM (Cytoplasmic)  Protein 
Expression 
                   
 
 
Unadjusted 
   P-Values 
 
 
*Adjusted  
P-Values 
Low 
(n=571) 
N (%) 
 
High 
(n=686) 
N (%) 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 59 (6.9) 
274 (48.1) 
219 (38.4) 
18 (3.2) 
 
69 (8.5) 
325 (51.8) 
235 (37.9) 
13 (1.8) 
 
0.204 
 
0.343 
Tumour Stage                                
1 
2 
3 
 
 
360 (63.0) 
158 (27.7) 
53 (9.3) 
 
418 (61.1) 
181 (30.4) 
62 (8.5) 
 
0.545 
 
0.789 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
105 (18.4) 
187 (32.8) 
278 (48.8) 
 
104 (15.2) 
210 (30.7) 
369 (54.0) 
 
0.137 
 
0.274 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
210 (31.3) 
104 (17.6) 
251 (51.5) 
  
220 (36.5) 
119 (19.4) 
342 (44.0) 
 
0.108 
 
0.238 
Tubule Formation                         
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
31 (5.5) 
190 (33.6) 
344 (60.9) 
 
37 (5.4) 
230 (33.8) 
414 (60.8) 
 
0.998 
 
41.91 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
18 (3.2) 
234 (41.4) 
313 (55.4) 
 
10 (1.5) 
233 (34.3) 
436 (64.2) 
 
0.002 
 
0.012 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
275 (56.8) 
94 (19.4) 
12 (2.5) 
58 (12.0) 
45 (9.3) 
 
374 (61.8) 
125 (20.7) 
15 (2.5) 
35 (5.8) 
56 (9.3) 
 
0.009 
 
0.034 
Lymphovascular Invasion            
No 
Yes 
 
363 (65.1) 
195 (34.9) 
 
453 (66.6) 
227 (33.4) 
 
0.564 
 
0.789 
B) Aggressive phenotype 
 
 
Her2 overexpression                     
No 
Yes 
 
495 (88.9) 
62 (11.1) 
 
595 (88.9) 
74 (11.1) 
 
0.969 
 
1.02 
Triple Negative Phenotype           
No 
Yes 
 
454 (80.9) 
107 (19.1) 
 
533 (80.6) 
128 (19.4) 
 
0.897 
 
0.99 
Basal Like Phenotype           
No 
Yes 
 
476 (87.8) 
66 (12.2) 
 
554 (86.3) 
88 (13.7) 
 
0.436 
 
0.704 
Cytokeratin 6 (CK6)                     
Negative 
Positive 
 
391 (83.4) 
78 (16.6) 
 
500 (84.2) 
94 (15.8) 
 
0.723 
 
0.893 
Cytokeratin 14 (CK14)                 
Negative 
Positive 
 
396 (85.7) 
66 (14.3) 
 
522 (88.5) 
68 (11.5) 
 
0.183 
 
0.334 
Cytokeratin 18 (CK18)                 
Negative 
Positive 
 
55 (12.5) 
385 (87.5) 
 
 
48 (9.0) 
486 (91.0) 
 
0.076 
 
0.187 
Cytokeratin 19 (CK19)                 
Negative 
Positive 
 
35 (7.4) 
436 (92.6) 
 
31 (5.3) 
555 (94.7) 
 
0.153 
 
0.292 
C) Hormone receptors 
 
 
 
ER               
Negative 
Positive 
 
150 (26.5) 
415 (73.5) 
 
180 (26.7) 
493 (73.3) 
 
0.938 
 
1.01 
PgR                                   
Negative 
Positive 
 
238 (44.2) 
300 (55.8) 
 
271 (43.1) 
358 (56.9) 
 
0.692 
 
0.880 
AR                     
Negative 
Positive 
 
 
170 (38.3) 
274 (61.7) 
 
201 (36.4) 
351 (63.6) 
 
0.543 
 
0.884 
D) DNA Repair 
 
 
BRCA1                     
Absent 
 Normal 
 
79 (20.2) 
312 (79.8) 
 
93 (18.9) 
400 (81.1) 
 
0.617 
 
0.835 
XRCC1                             
Low 
High 
 
84 (20.1) 
333 (79.9) 
 
69 (13.9) 
428 (86.1) 
 
0.012 
 
0.039 
FEN1                   
Low 
High 
 
309 (77.8) 
88 (22.2) 
 
321 (69.9) 
138 (30.1) 
 
0.009 
 
0.031 
SMUG1                  
Low 
High 
 
 
155 (41.4) 
219 (58.6) 
 
 
150 (35.0) 
279 (65.0) 
 
0.059 
 
0.154 
 
APE1 
Low 
High 
 
278 (57.3) 
207 (42.7) 
 
254 (43.4) 
331 (56.6) 
 
6.0X10-6 
 
1.0X10-5 
PolB 
Low 
High 
 
 
203 (40.2) 
302 (59.8) 
 
221 (36.5) 
385 (63.5) 
 
0.203 
 
0.355 
ATR  
Low 
High 
 
382 (73.3) 
139 (26.7) 
 
315 (61.6) 
204 (38.4) 
 
2.4X10-5 
 
0.0003 
ATM  
Low 
High 
 
182 (53.4) 
159 (46.6) 
 
220 (52.3) 
201 (47.7) 
 
0.759 
 
0.884 
DNA-PK  
Low 
High 
 
184 (39.0) 
288 (61.0) 
 
192 (32.5) 
399 (67.5) 
 
0.028 
 
0.084 
E) Cell cycle/apoptosis regulators 
 
 
P16 
Low 
High 
 
338 (86.4) 
53 (13.6) 
 
405 (86.4) 
64 (13.6) 
 
0.969 
 
0.992 
P21 
Low 
High 
 
235 (57.5) 
174 (42.5) 
 
283 (57.4) 
210 (42.6) 
 
0.76 
 
0.86 
MIB1                       
Low 
High 
 
238 (50.1) 
237 (49.9) 
 
233 (41.3) 
331 (58.7) 
 
0.005 
 
0.021 
P53              
Low expression 
High expression 
           
 
370 (81.0) 
87 (19.0) 
 
431 (76.4) 
133 (23.6) 
 
0.079 
 
0.184 
Bcl-2                            
Negative 
Positive 
 
175 (35.1) 
324 (64.9) 
 
226 (36.5) 
393 (63.5) 
 
0.618 
 
0.811 
TOP2A                    
Low 
Overexpression 
 
 
193 (49.6) 
196 (50.4) 
 
208 (42.3) 
284 (57.7) 
 
0.030 
 
0.084 
pCHK1 (Nuclear)                       
Low 
High 
 
458 (80.2) 
113 (19.8) 
 
573 (83.5) 
113 (16.5) 
 
0.127 
 
0.266 
pCHK1 (Cytoplasmic)                  
Low 
High 
 
187 (32.7) 
384 (67.3) 
 
128 (18.7) 
558 (81.3) 
 
1.0X10-6 
 
1.0X10-5 
Non-phospho CHK1 (Cyto.)         
Low 
High 
 
243 (54.1) 
206 (45.9) 
 
246 (44.6) 
305 (55.4) 
 
0.003 
 
0.015 
CHK2                       
Low 
High 
 
217 (54.1) 
184 (45.9) 
 
205 (40.2) 
305 (59.8) 
 
2.9X10-5 
 
2.0X10-4 
Bax                         
Low 
High 
 
237 (76.0) 
75 (24.0) 
 
270 (66.0) 
139 (34.0) 
 
0.004 
 
0.018 
CDK1                            
Low 
High 
 
 
240 (70.6) 
100 (29.4) 
 
310 (68.3) 
144 (31.7) 
 
0.486 
 
0.756 
CDK18 (Cytoplasmic)                   
Low 
High 
 
367 (81.7) 
82 (18.3) 
 
377 (69.3) 
167 (30.7) 
 
7.0X10-6 
 
1.0X10-4 
RECQL5                  
Low 
High 
 
235 (53.5) 
204 (46.5) 
 
227 (42.0) 
313 (58.0) 
 
3.4X10-4 
 
2.4X10-3 
MDM2                          
Low 
Overexpression 
 
296 (75.1) 
98 (24.9) 
 
362 (76.1) 
114 (23.9) 
 
0.752 
 
0.902 
Bold = Statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human epidermal 
growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; 
Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER-
/PgR-/HER2- . *Adjusted p values were calculated using Benjamini-Hochberg method to adjust for 
multiple testing. 
  
Supplementarty Table S7. BLM (nuclear and cytoplasmic protein co-expression) in breast 
cancer 
  
   
 
                    VARIABLE 
 
BLM  Protein Expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) Nuc-/Cyto- 
( n= 332) 
N (%) 
Nuc+/Cyto- 
(n=360) 
N (%) 
Nuc-
/Cyto+ 
(n=353) 
N (%) 
 
Nuc+/Cyto+ 
(n=333) 
N (%) 
 
A) Pathological    Parametersic 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 29 (8.7) 
163 (49.1) 
127 (38.3) 
13 (3.9) 
 
30 (12.6) 
111 (46.6) 
92 (38.7) 
5 (2.1) 
 
21 (6.0) 
182 (52.0) 
138 (39.4) 
9 (2.6) 
 
37 (11.1) 
172 (51.7) 
121 (36.3) 
3 (0.9) 
 
0.065 
 
0.083 
Tumour Stage                         
1 
2 
3 
 
 
207 (62.3) 
92 (27.7) 
33 (9.9) 
 
153 (64.0) 
66 (27.6) 
20 (8.4) 
 
215 (61.3) 
106 (30.2) 
30 (8.5) 
 
203 (61.0) 
102 (30.6) 
28 (8.4) 
 
0.946 
 
39.73 
Tubule Formation                  
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
17 (5.2) 
107 (32.6) 
204 (62.2) 
 
14 (5.9) 
83 (35.0) 
140 (59.1) 
 
17 (4.9) 
112 (32.1) 
220 (63.0) 
 
20 (6.0) 
118 (35.5) 
194 (58.4) 
 
0.90 
 
0.92 
Pleomorphism                         
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
12 (3.7) 
112 (34.1) 
204 (62.2) 
 
6 (2.5) 
122 (51.5) 
109 (46.0) 
 
2 (0.6) 
119 (34.2) 
227 (65.2) 
 
8 (2.4) 
114 (34.4) 
209 (63.1) 
 
1.2X10-5 
 
1.0X10-5 
Lymphovascular Invasion     
No 
Yes 
 
219 (67.2) 
107 (32.8) 
 
144 (62.1) 
88 (37.9) 
 
235 (67.9) 
111 (32.1) 
 
218 (65.3) 
116 (34.7) 
 
0.486 
 
0.551 
B) Aggressive phenotype 
Her2 overexpression                  
No 
Yes 
 
290 (89.2) 
35 (10.8) 
 
205 (88.4) 
27 (11.6) 
 
313 (90.5) 
33 (9.5) 
 
282 (87.3) 
41 (12.7) 
 
0.617 
 
0.664 
Basal Like Phenotype           
No 
Yes 
 
260 (83.3) 
52 (16.7) 
 
216 (93.9) 
14 (6.1) 
 
267 (82.2) 
58 (17.8) 
 
 
287 (90.5) 
30 (9.5) 
 
2.9X10-5 
 
1.0X10-4 
Cytokeratin 6 (CK6)                  
Negative 
Positive 
 
223 (79.6) 
57 (20.4) 
 
168 (88.9) 
21 (11.1) 
 
252 (81.0) 
59 (19.0) 
 
 
248 (87.6) 
35 (12.4) 
 
0.007 
 
0.011 
Cytokeratin 18 (CK18)              
Negative 
Positive 
 
49 (18.6) 
215 (81.4) 
 
 
6 (3.4) 
170 (96.6) 
 
35 (12.5) 
245 (87.5) 
 
13 (5.1) 
241 (94.9) 
 
1.0X10-6 
 
1.0X10-5 
Cytokeratin 19 (CK19)              
Negative 
Positive 
 
29 (10.2) 
254 (89.8) 
 
6 (3.2) 
182 (96.8) 
 
17 (5.5) 
291 (94.5) 
 
14 (5.0) 
264 (95.0) 
 
0.008 
 
0.012 
C) Hormone receptors 
PR                                   
Negative 
Positive 
 
151 (47.6) 
166 (52.4) 
 
87 (39.4) 
134 (60.6) 
 
156 (48.0) 
169 (52.0) 
 
115 (37.8) 
189 (62.2) 
 
0.016 
 
0.022 
AR                     
Negative 
Positive 
 
126 (47.0) 
142 (53.0) 
 
44 (25.0) 
316 (75.0) 
 
122 (42.2) 
167 (57.6) 
 
79 (30.0) 
184 (70.0) 
 
1.0X10-6 
 
1.0X10-5 
 D) DNA Repair 
ATM 
Low 
High 
 
109 (54.0) 
93 (46.0) 
 
73 (52.5) 
66 (47.5) 
 
114 (50.2) 
113 (49.8) 
 
106 (54.6) 
88 (45.4) 
 
0.806 
 
0.846 
E) Cell cycle/apoptosis regulators 
P16 
Low 
High 
 
199 (81.9) 
44 (18.1) 
 
139 (93.9) 
9 (6.1) 
 
197 (79.8) 
50 (20.2) 
 
208 (93.7) 
14 (6.3) 
 
 
1.0X10-6 
 
1.0X10-5 
pCHK1 (Nuclear)                       
Low 
High 
 
298 (90.0) 
33 (10.0) 
 
160 (66.7) 
80 (33.3) 
 
318 (90.3) 
34 (9.7) 
 
255 (76.3) 
79 (23.7) 
 
1.0X10-6 
 
1.0X10-5 
pCHK1 (Cytoplasmic)               
Low 
High 
 
123 (37.2) 
208 (62.8) 
 
64 (26.7) 
176 (73.3) 
 
68 (19.3) 
284 (80.7) 
 
60 (18.0) 
274 (82.0) 
 
1.0X10-6 
 
1.0X10-5 
Non-phospho CHK1                   
Low 
High 
 
151 (57.0) 
114 (43.0) 
 
92 (50.0) 
92 (50.0) 
 
133 (47.3) 
148 (52.7) 
 
113 (41.9) 
157 (58.1) 
 
0.005 
 
0.008 
CHK2                       
Low 
High 
 
145 (59.7) 
98 (40.3) 
 
72 (45.6) 
86 (54.4) 
 
113 (42.2) 
155 (57.8) 
 
92 (38.0) 
150 (62.0) 
 
9.0X10-6 
 
1.0X10-5 
Bax                         
Low 
High 
 
138 (75.4) 
123 (24.6) 
 
99 (76.7) 
30 (23.3) 
 
134 (63.2) 
78 (36.8) 
 
136 (69.0) 
61 (31.0) 
 
0.018 
 
0.024 
CDK18 (Cytoplasmic)                
Low 
High 
 
223 (84.8) 
40 (15.2) 
 
144 (77.4) 
42 (22.6) 
 
203 (72.5) 
77 (27.5) 
 
174 (65.9) 
90 (34.1) 
 
7.0X10-6 
 
1.0X10-5 
RECQL5                        
Low 
High 
161 (63.6) 
92 (36.4) 
74 (39.8) 
112 (60.2) 
134 (48.9) 
140 (51.1) 
93 (35.0) 
173 (65.0) 
1.0X10-6 1.0X10-5 
MDM2                          
Low 
Overexpression 
 
184 (76.3) 
57 (23.7) 
 
112 (73.2) 
41 (26.8) 
 
202 (78.3) 
56 (21.7) 
 
160 (73.4) 
58 (26.6) 
 
0.544 
 
0.601 
Bold = statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; 
Triple negative: ER-/PgR-/HER2- . Adjusted p values were calculated using Benjamini-
Hochberg false discovery rate method to adjust for multple testing. *Fischer test was used to 
obtain p values where one or more of cells has an expected frequency of five or less.  
  
Supplementary Table S8. BLM - Rad51 nuclear co-expression and breast cancer  
 
   
 
                    VARIABLE 
 
BLM-Rad51(Nuclear) Protein Co-Expression 
 
 
 
P- value 
 
 
 
P -Value 
(Adjusted) BLM-
/Rad51- 
(n=107) 
N (%) 
BLM+ 
/Rad51- 
(n=295) 
N (%) 
 
BLM-
/Rad51+ 
(n=88) 
N (%) 
 
BLM+ 
/Rad51+ 
(n=273) 
N (%) 
 
A) Pathological    Parameters 
Tumour Size  
 ≤1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 6 (5.6) 
49 (45.8) 
49 (45.8) 
3 (2.8) 
 
18 (8.0) 
97 (43.1) 
106 (49.1) 
4 (1.8) 
 
4 (5.6) 
49 (69.0) 
16 (22.5) 
2 (2.8) 
 
26 (9.8) 
138 (52.3) 
99 (37.5) 
1 (0.4) 
 
0.004 
 
0.008 
Tumour Stage                        
1 
2 
3 
 
 
65 (60.7) 
30 (28.0) 
12 (11.2) 
 
116 (51.3) 
88 (38.9) 
22 (9.7) 
 
46 (63.9) 
23 (31.9) 
3 (4.2) 
 
153 (58.0) 
85 (32.2) 
26 (9.8) 
 
0.251 
 
0.326 
Tumour Grade                       
 G1 
 G2 
 G3 
  
 
9 (16.0) 
21 (26.2) 
77 (57.8) 
 
27 (11.9) 
70 (31.0) 
129 (57.1) 
 
9 (12.7) 
22 (31.0) 
40 (56.3) 
 
48 (18.2) 
103 (39.0) 
113 (42.8) 
 
7.0X10-5 
 
3.0X10-4 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-
18) 
M3 (high; mitosis >18) 
 
16 (15.2) 
19 (18.1) 
70 (66.7) 
  
65 (29.7) 
42 (19.2) 
112 (51.1) 
 
19 (27.1) 
10 (14.3) 
41 (58.6) 
 
103 (39.8) 
51 (19.7) 
105 (40.5) 
 
1.0X10-4 
 
3.0X10-4 
Tubule Formation                 
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
2 (1.9) 
30 (28.6) 
73 (69.5) 
 
9 (4.1) 
65 (35.0) 
145 (66.2) 
 
3 (4.3) 
24 (34.3) 
43 (61.4) 
 
12 (4.6) 
97 (37.5) 
150 (57.9) 
 
0.366 
 
4.75 
Pleomorphism                        
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
0 (0.0) 
26 (25.0) 
78 (75.0) 
 
0 (0.0) 
78 (35.6) 
141 (64.4) 
 
1 (1.4) 
24 (34.3) 
45 (64.3) 
 
4 (1.6) 
111 (43.0) 
143 (55.4) 
 
0.011 
 
0.02 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
81 (75.7) 
8 (7.5) 
7 (6.5) 
4 (3.8) 
7 (6.5) 
 
142 (62.8) 
37 (16.4) 
5 (2.2) 
23 (10.1) 
23 (9.5) 
 
47 (65.3) 
13 (18.1) 
1 (1.4) 
6 (8.4) 
21 (6.8) 
 
139 (52.7) 
69 (26.2) 
3 (1.2) 
27 (10.3) 
35 (9.6) 
 
0.040 
 
0.06 
Lymph Node Status               
Negative 
Positive (1-3) 
Positive (>3) 
 
52 (61.9) 
26 (31.0) 
6 (7.1) 
 
198 (50.3) 
80 (41.0) 
17 (8.7) 
 
38 (61.3) 
23 (37.1) 
1 (1.6) 
 
135 (56.3) 
88 (36.7) 
17 (7.1) 
 
0.320 
 
0.34 
B) Aggressive Phenotype 
Her2 overexpression              
No 
Yes 
 
97 (90.7) 
10 (9.3) 
 
184 (82.9) 
38 (17.1) 
 
62 (87.3) 
9 (12.7) 
 
217 (84.4) 
40 (15.6) 
 
0.278 
 
0.319 
Triple Negative Phenotype   
No 
Yes 
 
88 (82.2) 
19 (17.8) 
 
191 (84.5) 
35 (15.5) 
 
54 (75.0) 
18 (25.0) 
 
228 (86.4) 
36 (13.6) 
 
0.129 
 
0.18 
NPI           
≤3.4 
>3.4 
 
14 (14.1) 
85 (85.9) 
 
49 (22.6) 
168 (77.4) 
 
19 (27.5) 
50 (72.5) 
 
 
86 (34.0) 
167 (66.0) 
 
0.001 
 
0.0026 
C) Hormone Receptors 
ER               
Negative 
Positive 
 
49 (47.1) 
55 (52.9) 
 
67 (30.5) 
153 (69.5) 
 
21 (30.9) 
47 (69.1) 
 
46 (17.9) 
211 (82.1) 
 
3.8X10-7 
 
1.0X10-5 
PR                                   
Negative 
Positive 
 
65 (64.4) 
36 (35.6) 
 
102 (47.9) 
111 (52.1) 
 
30 (42.9) 
40 (57.1) 
 
89 (35.3) 
163 (64.7) 
 
1.0X10-5 
 
1.0X10-4 
Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: oestrogen 
receptor; PgR: progesterone receptor; Triple negative: ER-/PgR-/HER2- . *Adjusted p values were 
calculated using Benjamini-Hochberg false discovery rate method to adjust for multple testing.  
 
 
 
  
Supplementary Table S9: Multivariate analysis in Nottingham cohort. 
 
 P value Exp (B)* 95% CI of Exp (B) 
Lower Upper 
Breast Cancer Specific Survival 
 
Stage 9.8x10-8 1.990 1.545 2.563 
Grade 1.8x10-5 1.816 1.383 2.385 
HER2 expression .001 1.923 1.304 2.835 
BLM protein (Nuclear) .026 .684 .489 .955 
BLM protein (Cytoplasmic) .523 .891 .626 1.269 
Rad51 protein (Nuclear) .156 .797 .583 1.091 
Rad51 protein (Cytoplasmic) .545 1.266 .590 2.717 
ER status .061 1.421 .985 2.050 
Lymph node status .109 1.275 .947 1.715 
 
*B (is a regression coefficient) - These are the values for the logistic regression equation for 
predicting the dependent variable from the independent variable.  They are in log-odds units. Exp(B) - 
These are the odds ratios for the predictors.  They are the exponentiation of the coefficients. 
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Supplementary Figure Legends 
 
Supplementary Figure S1: A. Forest plot showing prognosis based on BLM protein 
expression in external validation cohort (n=2413). B. Kaplan Meier curves showing 
metastatic relapse free survival based on BLM protein expression in external validation 
cohort (n=2413). 
 
Supplementary Figure S2: A1. Western blot of BLM expression in four breast cancer cell 
lines; MCF-7, MDA-MB-231, MDA-MB-436 and MDA-MB-468.  All experiments were run 
in duplicates. Cells lysates were prepared from 2 million cells and 5 μl of cell lysate was 
loaded on to the gel ; A2. Relative protein expression of BLM in breast Cancer cell lines; A3. 
Relative mRNA expression of BLM in Breast Cancer cell lines. All experiments were run in 
triplicates. B1. Normal breast tissue showing strong nuclear BLM staining. B2. 
Microphotograph of BLM nuclear and BLM cytoplasm negative breast cancer; B3. 
Microphotograph of BLM nuclear negative and BLM cytoplasm positive breast cancer; B4. 
Microphotograph of BLM nuclear positive and BLM cytoplasm negative breast cancer; B5. 
Microphotograph of BLM nuclear positive and BLM cytoplasm positive breast cancer. 
 
Supplementary Figure S3: Kaplan Meier curves showing BCSS based on BLM protein 
expression in A. ER+ patients with NPI >3.4, who received no endocrine therapy; B. ER+ 
patients with NPI >3.4, who received endocrine therapy; C. ER- patients with NPI>3.4, who 
received no chemotherapy; D. ER- patients with NPI >3.4, who received chemotherapy. 
 
Supplementary Figure S4: Kaplan Meier curves showing BCSS based on BLM/Rad51 
protein co-expression in A. whole cohort; B. ER- cohort with NPI >3.4; C. ER- patients with 
NPI >3.4, who received no chemotherapy; D. ER- patients with NPI >3.4, who received 
chemotherapy. 
 
2 
 
Supplementary Figure S5: Kaplan Meier curves showing BCSS based on BLM/Rad51 
protein co-expression in A. ER+ cohort; B. ER+ patients with NPI >3.4, who received no 
endocrine therapy; C. ER+ patients with NPI >3.4, who received endocrine therapy. 
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BLM mRNA expression (Forest Plot) 
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Supplementary Figure S1 
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Supplementary Figure S2 
BLM  
β-Actin 
 
Relative BLM protein expression Relative BLM mRNA expression 
A1 
A2 A3 
B5 
ER+; NPI>3.4; no endocrine therapy        
Log Rank = 8.536; P = 0.036 
ER+; NPI>3.4; had endocrine therapy        
Log Rank = 2.232 ; P = 0.526 
ER-; NPI>3.4; no chemotherapy 
Log Rank = 5.723 ; P = 0.126 
ER-; NPI>3.4; had chemotherapy 
Log Rank = 3.30 ; P = 0.348 
Supplementary Figure S3 
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C D 
--- Bn+/Bc+ (n=65) 
--- Bn+/Bc- (n=34) 
--- Bn-/Bc+ (n=54) 
--- Bn-/Bc- (n=54) 
--- Bn+/Bc+ (n=98) 
--- Bn+/Bc- (n=66) 
--- Bn-/Bc+ (n=104) 
--- Bn-/Bc- (n=84) 
--- Bn+/Bc+ (n=89) 
--- Bn+/Bc- (n=40) 
--- Bn-/Bc+ (n=102) 
--- Bn-/Bc- (n=105) 
--- Bn+/Bc+ (n=62) 
--- Bn+/Bc- (n=60) 
--- Bn-/Bc+ (n=95) 
--- Bn-/Bc- (n=59) 
BLM Nu/Rad51 co-expression in Whole Cohort 
 Bn+/Rn+ (n=254) 
Bn+/Rn- (n=220) 
Log Rank = 13.39; P = 0.004 
Bn-/Rn+ (n=69) 
Bn-/Rn- (n=101) 
 
 
NPI>3.4;  ER- Cohort 
 Bn+/Rn+ (n=41) 
Bn+/Rn- (n=62) 
Log Rank = 2.33 ; P = 0.506 
Bn-/Rn+ (n=16) 
Bn-/Rn- (n=41) 
NPI>3.4; ER- Cohort; no chemotherapy 
 Bn+/Rn+ (n=26) 
Bn+/Rn- (n=49) 
Log Rank = 1.86 ; P = 0.602  
Bn-/Rn+ (n=10) 
Bn-/Rn- (n=29) 
NPI>3.4; ER- Cohort; had chemotherapy 
 Bn+/Rn+ (n=9) 
Bn+/Rn- (n=9) 
Log Rank = 9.41 ; P = 0.02  
Bn-/Rn+ (n=5) 
Bn-/Rn- (n=8) 
B A 
C D 
S4Supplementary Figure S4 
BLM Nu/Rad51 co-expression in ER+ Cohort 
 Bn+/Rn+ (n=115) 
Bn+/Rn- (n=97) 
Log Rank = 3.45 ; P = 0.327 
Bn-/Rn+ (n=31) 
Bn-/Rn- (n=35) 
NPI>3.4; ER+ Cohort; no endocrine therapy 
 Bn+/Rn+ (n=32) 
Bn+/Rn- (n=32) 
Log Rank = 0.61 ; P = 0.89   
Bn-/Rn+ (n=9) 
Bn-/Rn- (n=11) 
NPI>3.4; ER+ Cohort; had endocrine therapy 
 Bn+/Rn+ (n=80) 
Bn+/Rn- (n=89) 
Log Rank = 2.15 ; P =  0.54 
Bn-/Rn+ (n=21) 
Bn-/Rn- (n=21) 
Supplementary Figure S5 
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